Antengene Corporation Limited Is A Global Biopharmaceutical Company Focused On Oncology Therapiesheadquartered With Operations In The U S Chinaand The Apac Regionantengene Is Dedicated To Discoveringdevelopingmanufacturingand Commercializing Innovative Cancer Treatmentsthe Company Employs A Workforce Of 394 And Operates As An Integrated Biotech Firm With A Strong Emphasis On Combination And Complementary R&D Strategies Antengene S Core Product Is Atg 010Selinexor A Selective Nuclear Export Inhibitor Approved By The Fda For Treating Relapsed Refractory Multiple Myeloma And Diffuse Large B Cell Lymphomathe Company Has A Robust Pipeline With 12 Clinical Stage Assetsincluding Atg 016 And Atg 527Targeting Various Cancers And Diseasesantengene S Manufacturing Capabilities Include Facilities For Small Molecules And Biologicsensuring A Consistent Supply Of Its Therapiesthe Company Markets Its Products Across Several Regionsincluding Chinahong Kongtaiwanaustraliasingaporeand South Koreawith Plans For Further Regulatory Submissions
